ELAHERE has a well-established safety profile to help YOU support your patients through treatment

Adverse REACTIONS in ≥10% of patients who received ELAHERE in MIRASOL1

The median duration of ELAHERE treatment was 5 months (range: 0.69 to 27.4)1

Adverse reaction

ELAHERE
(n=218)

Standard chemotherapy*
(n=207)

*Chemotherapy: paclitaxel, pegylated liposomal doxorubicin (PLD), topotecan.1

†Abdominal pain includes abdominal pain, abdominal pain upper, abdominal pain lower, and abdominal discomfort.1

‡Blurred vision includes vision blurred, vitreous floaters, visual acuity reduced, diplopia, accommodation disorder, and visual impairment.1

§Keratopathy includes corneal disorder, corneal epithelial microcysts, keratitis, keratopathy, corneal deposits, punctate keratitis, and corneal opacity.1

Dry eye includes dry eye and lacrimation increased.1

#Cataract includes cataract and cataract nuclear.1

||Fatigue includes fatigue and asthenia.1

**Peripheral neuropathy includes neuropathy peripheral, peripheral sensory neuropathy, peripheral motor neuropathy, paresthesia, hypoesthesia, polyneuropathy, neurotoxicity, and peripheral sensorimotor neuropathy.1

††Musculoskeletal pain includes back pain, myalgia, neck pain, arthralgia, musculoskeletal pain, noncardiac chest pain, bone pain, pain in extremity, musculoskeletal stiffness, musculoskeletal chest pain, and musculoskeletal discomfort.1

‡‡Pneumonitis includes pneumonitis, interstitial lung disease, respiratory failure, and organizing pneumonia.1

Laboratory abnormalities

Select laboratory abnormalities ≥10% for all grades in patients who received ELAHERE in MIRASOL1

Laboratory abnormality

ELAHERE
(n=218)

Standard chemotherapy
(n=207)

*The denominator used to calculate the rate varied from 63 to 214 (ELAHERE) and from 63 to 194 (IC chemotherapy) based on the number of patients with a baseline value and at least 1 posttreatment value.1

ALT=alanine aminotransferase; AST=aspartate aminotransferase; IC=investigator's choice.

Adverse reactions seen in MIRASOL

ELAHERE (n=218)1,2

Serious ARs (%)

24 (n=52)

Discontinuation due to ARs (%)

9 (n=20)

Common reasons for discontinuation (≥1%)

Pneumonitis (2%), blurred vision (1%), and peripheral neuropathy (1%)

Hazard icon

The most common (≥2%) serious ARs with ELAHERE were intestinal obstruction (5%), abdominal pain (3%), and pleural effusion (3%). Fatal ARs occurred in 3% of patients and included intestinal obstruction, dyspnea in the setting of subileus, neutropenic sepsis, cardiopulmonary failure, respiratory failure, ischemic stroke, and pulmonary embolus1

Infusion bag with down arrow icon

Dosage delays of ELAHERE due to an AR occurred in 54% of patients treated with ELAHERE. ARs that required dosage delays in ≥3% of patients included1:

  • Blurred vision (22%)
  • Keratopathy (19%)
  • Dry eye (7%)
  • Neutropenia (6%)
  • Pneumonitis (6%)
  • Photophobia (5%)
  • Cataract (4%)
  • Peripheral neuropathy (4%)

Down arrow icon

Dose reductions of ELAHERE due to an AR occurred in 34% of patients. ARs that required dose reductions in ≥3% of patients included1:

  • Blurred vision (22%)
  • Keratopathy (19%)
  • Peripheral neuropathy (6%)
  • Dry eye (7%)
Serious icon

Clinically relevant ARs that occurred in <10% of patients who received ELAHERE included infusion-related reactions/hypersensitivity (8%)1

Calendar icon

The median duration of ELAHERE treatment was 5 months (range: 0.69 to 27.4)1

AR=adverse reaction.

Additional adverse reactions of interest2,3

Adverse reactions reported in MIRASOL, in addition to safety data from the ELAHERE Prescribing Information

This analysis was not powered to demonstrate a difference in adverse reactions between ELAHERE and traditional chemotherapy.

General

Hair icon

Alopecia2,3

99% of patients did not have a reported hair loss with ELAHERE vs 86% of patients who did not have a reported hair loss with traditional chemotherapy

Gastrointestinal

Tongue icon

Stomatitis2,3

3% of patients treated with ELAHERE experienced
stomatitis vs 11% with standard chemotherapy

Hematologic

anemia icon

Anemia2,3

10% of patients treated with ELAHERE had anemia vs 34% with standard chemotherapy

Thrombocytopenia
icon

Thrombocytopenia2,3

7% of patients treated with ELAHERE had thrombocytopenia vs 16% with standard chemotherapy

neutropenia
icon

Neutropenia2,3

11% of patients treated with ELAHERE had neutropenia vs 29% with standard chemotherapy

Adverse reactions reported above were for all grades; ELAHERE (n=218), standard chemotherapy (n=207).2,3

OCULAR ADVERSE REACTIONS SEEN AND MANAGED ACROSS CLINICAL TRIALS1,2*

Graph icon

Ocular adverse reactions were mostly Grade 1 or 21,2

59% of patients treated with ELAHERE had an ocular adverse reaction; 11% of patients experienced Grade 3 ocular adverse reactions, 0.3% experienced Grade 4 reactions1

Eye icon

Nearly all ocular adverse reactions resolved to Grade 0 or 12

Of the patients treated with ELAHERE who had an ocular adverse reaction, 53% had complete resolution and 38% had partial improvement at last follow-up1†

Discontinuation due to ocular events icon

1% of patients discontinued ELAHERE due to ocular adverse reactions1

Median time icon

Median time to onset of the first ocular adverse reaction was 5.1 weeks (range: 0.1 to 68.6)1

Ocular adverse reactions seen in MIRASOL2,4

56% (n=122) of patients treated with ELAHERE experienced an ocular adverse reaction vs 9% of patients receiving standard chemotherapy.

  • Of the patients treated with ELAHERE who had an ocular adverse reaction, 51% had complete resolution and 42% had partial improvement
  • Of the remaining 7% (n=9/122) of patients who had no documented improvement, 67% were at final Grade 1 and 33% were at final Grade 2

This analysis was not powered to demonstrate a difference in adverse reactions between ELAHERE and traditional chemotherapy.

NO NEW SAFETY SIGNALS IDENTIFIED IN THE LONGER-TERM FOLLOW-UP (MEDIAN 30.5 MONTHS)5

Updated safety by treatment cohort in MIRASOL6

Adverse reaction

ELAHERE
(n=218)

Standard chemotherapy*
(n=207)

*Grade 3 events not applicable for alopecia.6

Long-term safety adverse reactions are preferred terms and not grouped terms.6

Additional data from the ELAHERE Prescribing Information include1:

  • Fatigue
    • ELAHERE: 47% (all grades), 3% (Grades 3-4)
    • Standard chemotherapy: 41% (all grades), 7% (Grades 3-4)
  • Peripheral neuropathy
    • ELAHERE: 37% (all grades), 4% (Grades 3-4)
    • Standard chemotherapy: 23% (all grades), 4% (Grades 3-4)

No inference can be drawn from this data set. Follow-up analysis is exploratory and data are descriptive in nature.

Updated safety overview in MIRASOL5

Adverse reaction, n (%)

ELAHERE (n=218)

Standard chemotherapy (n=207)

Any TEAR

211 (97)

194 (94)

Grade ≥3 TEAR

97 (44)

113 (55)

Serious TEARs

55 (25)

69 (33)

Treatment-related serious ARs

21 (10)

16 (8)

Dose reduction due to TEARs

77 (35)

50 (24)

Dose delays/holds due to TEARs

122 (56)

112 (54)

Discontinuations due to TEARs

25 (11)

31 (15)

Deaths on study drug or within 30 days of last dose

9 (4)

11 (5)

TEAR=treatment-emergent adverse reaction.

Long-term safety adverse reactions are preferred terms and not grouped terms.6

No inference can be drawn from this data set. Follow-up analysis is exploratory and data are descriptive in nature.

Resources for treatment

From eye care to access and reimbursement, information is available to support your patients and your practice.

How dose modifications can help

Dose modifications can help manage adverse reactions
and keep patients on treatment.